Sonpiretigene isteparvovec is under clinical development by Nanoscope Therapeutics and currently in Phase II for Juvenile Macular Degeneration (Stargardt Disease). According to GlobalData, Phase II drugs for Juvenile Macular Degeneration (Stargardt Disease) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Sonpiretigene isteparvovec LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sonpiretigene isteparvovec overview
Sonpiretigene isteparvovec (VMCO-1) is under development for the treatment of juvenile macular degeneration (Stargardt Disease), dry age-related macular degeneration (geographic atrophy), retinitis pigmentosa, usher syndrome and cone-rod dystrophy. It is administered by intravitreal route. The therapeutic candidate is a multi-characteristic broad-band light activatable white-opsin developed by MultiSite Gateway Technology. The technology uses a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks (ChR2 in blue, C1V1 in green and ReaChR in red).
Nanoscope Therapeutics overview
Nanoscope Therapeutics., is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight. The company is headquartered in United States.
For a complete picture of Sonpiretigene isteparvovec’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
